Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates
- PMID: 2069384
- PMCID: PMC245095
- DOI: 10.1128/AAC.35.4.764
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates
Abstract
The in vitro activities of three new quinolones (sparfloxacin, CI-960, and PD 131,628) were compared with that of ciprofloxacin against 5,252 routine clinical aerobic and facultatively anaerobic bacterial isolates. Overall, CI-960 was the most active drug in vitro (MIC for 90% of the strains tested, 0.13 micrograms/ml); ciprofloxacin and sparfloxacin were the least active (MIC for 90% of the strains tested, 1.0 micrograms/ml). All three new quinolones, but particularly CI-960 and PD 131,628, exhibited significantly greater activity than ciprofloxacin against enterococci and staphylococci.
Similar articles
-
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955. Antimicrob Agents Chemother. 1991. PMID: 1906696 Free PMC article.
-
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.Antimicrob Agents Chemother. 1992 May;36(5):1158-62. doi: 10.1128/AAC.36.5.1158. Antimicrob Agents Chemother. 1992. PMID: 1324640 Free PMC article.
-
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k. Diagn Microbiol Infect Dis. 1993. PMID: 8395375
-
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.J Antimicrob Chemother. 1993 Apr;31(4):505-22. doi: 10.1093/jac/31.4.505. J Antimicrob Chemother. 1993. PMID: 7605398
-
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.Antimicrob Agents Chemother. 2004 Feb;48(2):369-77. doi: 10.1128/AAC.48.2.369-377.2004. Antimicrob Agents Chemother. 2004. PMID: 14742182 Free PMC article. Review. No abstract available.
Cited by
-
Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.J Clin Microbiol. 1995 Jan;33(1):235-8. doi: 10.1128/jcm.33.1.235-238.1995. J Clin Microbiol. 1995. PMID: 7699050 Free PMC article.
-
Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522. Infection. 1999. PMID: 10378126 Review. No abstract available.
-
In vitro antistaphylococcal activities of two investigative fluoroquinolones, CI-960 and WIN 57273, compared with those of ciprofloxacin, mupirocin (pseudomonic acid), and peptide-class antimicrobial agents.Antimicrob Agents Chemother. 1992 Apr;36(4):851-3. doi: 10.1128/AAC.36.4.851. Antimicrob Agents Chemother. 1992. PMID: 1323955 Free PMC article.
-
Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.Antimicrob Agents Chemother. 1992 Jun;36(6):1325-8. doi: 10.1128/AAC.36.6.1325. Antimicrob Agents Chemother. 1992. PMID: 1329621 Free PMC article.
-
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.Antimicrob Agents Chemother. 1996 Jun;40(6):1564-8. doi: 10.1128/AAC.40.6.1564. Antimicrob Agents Chemother. 1996. PMID: 8726042 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical